WTX-124
Advanced or metastatic solid tumors
Key Facts
About Werewolf Therapeutics
Werewolf Therapeutics is advancing a new class of cancer immunotherapies engineered to be conditionally activated within the tumor microenvironment. Its lead programs, WTX-124 and WTX-330, are systemically inactive IL-2 and IL-12 pro-drugs, respectively, designed to deliver potent anti-tumor activity while minimizing severe side effects. The company is publicly traded on NASDAQ under the ticker HOWL and is progressing its pipeline through early clinical trials. Its strategy focuses on validating its PREDATOR™ platform to unlock the full therapeutic potential of cytokines in oncology.
View full company profileTherapeutic Areas
Other Advanced or metastatic solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| PRT3645 | Prelude Therapeutics | Phase 1 |
| CHECKvacc (CF33-hNIS-antiPDL1) | Imugene | Phase 1 |
| VAXINIA (CF33-hNIS) | Imugene | Phase 1 |